Colorectal disorders:
Indications for: ENTYVIO
Moderately to severely active ulcerative colitis or Crohn’s disease.
Adult Dosage:
Give by IV infusion over 30mins. ≥18yrs: 300mg at Weeks 0, 2, and 6, then every 8 weeks thereafter. Discontinue if no therapeutic benefit by Week 14.
Children Dosage:
<18yrs: not established.
ENTYVIO Warnings/Precautions:
Complete all immunizations according to current guidelines before initiating. Monitor for hypersensitivity reactions during and after infusion. Have epinephrine and antihistamines available. Discontinue if anaphylaxis or other serious infusion-related or hypersensitivity reactions occur. Active, severe infections: not recommended until controlled. Consider withholding if severe infection develops. History of recurring severe infections. Consider tuberculosis screening. Monitor for neurological signs/symptoms (those associated with progressive multifocal leukoencephalopathy [PML]); withhold dosing if suspected; permanently discontinue if confirmed. Discontinue if jaundice or significant liver injury occurs. Pregnancy. Nursing mothers.
ENTYVIO Classification:
Integrin receptor antagonist.
ENTYVIO Interactions:
Avoid concomitant natalizumab, TNF blockers. Caution with concomitant live vaccines.
Adverse Reactions:
Nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities; infusion-related or hypersensitivity reactions, PML.
Note:
Register pregnant patients exposed to Entyvio by calling (877) 825-3327.
Generic Drug Availability:
NO
How Supplied:
Single-use vial (20mL)—1
